Since winning a pitch competition a year ago, Synthis Therapeutics has been working out of JLABS' Manhattan location on a TGF-β antibody drug conjugate

blonca9
Oct 21, 2024
1 min read

Founder & CEO Dori Thomas-Karyat describes why she believes a local delivery approach to the tumor is the solution to the shortcomings that other, mostly systemic, TGF-β programs have faced.

Recent Posts

See All

Humacyte CEO Laura Niklason updates us on the early days of the launch of Symvess, the company's bioengineered blood vessel product

Biotech veteran Harvey Berger was named Chairman & CEO of Arena BioWorks today - he describes how 'foraging to focusing' will be the name of the game

Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS

Since winning a pitch competition a year ago, Synthis Therapeutics has been working out of JLABS' Manhattan location on a TGF-β antibody drug conjugate

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight